antibody–drug conjugates for cancer therapy
Clicks: 184
ID: 155133
2016
Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.
| Reference Key |
parslow2016biomedicinesantibodydrug
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Adam C. Parslow;Sagun Parakh;Fook-Thean Lee;Hui K. Gan;Andrew M. Scott |
| Journal | journal of healthcare engineering |
| Year | 2016 |
| DOI | 10.3390/biomedicines4030014 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.